IP6K1 Inhibition in Platelets for Lung Infection Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current host-modulating strategies for treating lung infections face challenges in balancing anti-pathogen effects with unwanted inflammation-induced tissue damage, particularly in reducing neutrophil accumulation in the lung, which is exacerbated by antimicrobial resistance.

Innovation Solution

Inhibition of inositol hexakisphosphate kinase 1 (IP6K1) in platelets, rather than neutrophils, reduces neutrophil accumulation in the lung, enhancing bacterial killing while minimizing lung damage, as demonstrated by administering an IP6K1 inhibitor, such as TNP, which targets platelets to alter platelet activity and reduce neutrophil recruitment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If host-modulating strategies are used to control immune response, then anti-pathogen effects are improved, but inflammation-induced tissue damage increases

Engineering Contradiction:

Improveanti-pathogen effectsVSAvoidinflammation-induced tissue damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the immune response modulation by specifically targeting platelet IP6K1 rather than systemically modulating all immune cells. This localized approach in platelets allows control of neutrophil recruitment without broadly suppressing other protective immune functions, thus improving anti-pathogen effects while reducing tissue damage.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention applies local quality by using platelet-specific IP6K1 inhibition to alter platelet activity in a targeted manner. This creates a localized effect on neutrophil recruitment to the lung without affecting other immune cells systemically, resolving the contradiction between effective pathogen control and reduction of inflammatory damage.

Inventive Principle:

Principle #3Local quality

2Object-generated harmful factors

If IP6K1 is inhibited in neutrophils, then inflammatory activity increases, but neutrophil accumulation increases

Engineering Contradiction:

Improveinflammatory activityVSAvoidneutrophil accumulation

Core Design Contradiction:

Object-generated harmful factorsVSQuantity of substance

Solution Approach 1:

The invention uses platelets as an intermediary to control neutrophil behavior. By inhibiting IP6K1 in platelets, the invention indirectly modulates neutrophil recruitment and activation without directly affecting neutrophil IP6K1. This intermediary approach resolves the contradiction by using platelets as a mediator to reduce neutrophil accumulation while controlling inflammatory activity.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If antimicrobial resistance increases, then treatment effectiveness decreases, but inflammation-induced tissue damage increases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidinflammation-induced tissue damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention enables the host immune system to serve itself more effectively by modulating platelet function to enhance neutrophil-mediated bacterial killing. This host-modulating approach restores effective anti-pathogen defense without relying on antibiotics, while simultaneously reducing excessive inflammatory damage through targeted platelet IP6K1 inhibition.

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS11357780B2Methods and compositions relating to the inhibition of IP6K1

Publication Date: 2022.06.14 CHILDRENS MEDICAL CENT CORP

AI summary

The technology described herein is directed to methods of treating lung infections and/or lung inflammation (e.g, pneumonia) by inhibiting IP6K1.